Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“ Ault Alliance ” or the “ Company ”), is proud to announce that Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”)...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”),...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”),...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”),...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”),...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s...
BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“ BitNile ” or the “ Company ”), today announced its plan to merge its wholly owned subsidiary, Ault Alliance, Inc....
BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“ BitNile ” or the “ Company ”), reported its financial results for the third quarter ended September 30, 2022 on its...